08.02.13
Alphaeon Corporation, a wholly-owned subsidiary of Strathspey Crown Holdings, LLC, announced today that it has acquired an exclusive United States license for the full line of products from Geneva-based Teoxane Laboratories.
In addition to the partnership agreement, Teoxane founder and chairwoman Valerie Taupin will join the Alphaeon Board of Directors.
Teoxane Laboratories is recognized as an innovator of hyaluronic acid-based wrinkle-filling products currently available in 90 markets outside of the United States.
"The partnership is a great fit...both companies possess an unparalleled commitment to delivering science-based, high-quality medical aesthetic products," said Robert E. Grant, chief executive officer, Alphaeon.
Grant continued, "During the past ten years, Teoxane has gained significant market presence and leadership in Europe, capturing the number two market position in several western European countries for its broad range of next-generation hyaluronic acid dermal fillers and innovative cosmeceuticals. The Teoxane transaction advances Alphaeon's vision to bring highly innovative lifestyle healthcare products, combined with value-added services, to serve patients."
As part of the relationship, Alphaeon will market the full line of Teoxane hyaluronic acid-based dermal fillers and cosmeceutical products to credentialed physician specialists (CPSs). Other terms of the license acquisition are not being disclosed.
Teoxane products contain 100 percent non-animal origin, resorbable hyaluronic acid. Hyaluronic acid dermal fillers are the most widely used aesthetic fillers worldwide.
In addition to the partnership agreement, Teoxane founder and chairwoman Valerie Taupin will join the Alphaeon Board of Directors.
Teoxane Laboratories is recognized as an innovator of hyaluronic acid-based wrinkle-filling products currently available in 90 markets outside of the United States.
"The partnership is a great fit...both companies possess an unparalleled commitment to delivering science-based, high-quality medical aesthetic products," said Robert E. Grant, chief executive officer, Alphaeon.
Grant continued, "During the past ten years, Teoxane has gained significant market presence and leadership in Europe, capturing the number two market position in several western European countries for its broad range of next-generation hyaluronic acid dermal fillers and innovative cosmeceuticals. The Teoxane transaction advances Alphaeon's vision to bring highly innovative lifestyle healthcare products, combined with value-added services, to serve patients."
As part of the relationship, Alphaeon will market the full line of Teoxane hyaluronic acid-based dermal fillers and cosmeceutical products to credentialed physician specialists (CPSs). Other terms of the license acquisition are not being disclosed.
Teoxane products contain 100 percent non-animal origin, resorbable hyaluronic acid. Hyaluronic acid dermal fillers are the most widely used aesthetic fillers worldwide.
